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Abstract: BACKGROUND Long-term outcomes after percutaneous coronary intervention (PCI) with
contemporary drug-eluting stents, as compared with coronary-artery bypass grafting (CABG), in patients
with left main coronary artery disease are not clearly established. METHODS We randomly assigned 1905
patients with left main coronary artery disease of low or intermediate anatomical complexity (according to
assessment at the participating centers) to undergo either PCI with fluoropolymer-based cobalt-chromium
everolimus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). The primary
outcome was a composite of death, stroke, or myocardial infarction. RESULTS At 5 years, a primary
outcome event had occurred in 22.0% of the patients in the PCI group and in 19.2% of the patients in the
CABG group (difference, 2.8 percentage points; 95% confidence interval [CI], -0.9 to 6.5; P = 0.13). Death
from any cause occurred more frequently in the PCI group than in the CABG group (in 13.0% vs. 9.9%;
difference, 3.1 percentage points; 95% CI, 0.2 to 6.1). In the PCI and CABG groups, the incidences of
definite cardiovascular death (5.0% and 4.5%, respectively; difference, 0.5 percentage points; 95% CI, -1.4
to 2.5) and myocardial infarction (10.6% and 9.1%; difference, 1.4 percentage points; 95% CI, -1.3 to 4.2)
were not significantly different. All cerebrovascular events were less frequent after PCI than after CABG
(3.3% vs. 5.2%; difference, -1.9 percentage points; 95% CI, -3.8 to 0), although the incidence of stroke was
not significantly different between the two groups (2.9% and 3.7%; difference, -0.8 percentage points; 95%
CI, -2.4 to 0.9). Ischemia-driven revascularization was more frequent after PCI than after CABG (16.9%
vs. 10.0%; difference, 6.9 percentage points; 95% CI, 3.7 to 10.0). CONCLUSIONS In patients with
left main coronary artery disease of low or intermediate anatomical complexity, there was no significant
difference between PCI and CABG with respect to the rate of the composite outcome of death, stroke,
or myocardial infarction at 5 years. (Funded by Abbott Vascular; EXCEL ClinicalTrials.gov number,
NCT01205776.).
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Stone, Gregg W; Kappetein, A Pieter; Sabik, Joseph F; Pocock, Stuart J; Morice, Marie-Claude; Puskas,
John; Kandzari, David E; Karmpaliotis, Dimitri; Brown, W Morris; Lembo, Nicholas J; Banning, Adrian;
Merkely, Béla; Horkay, Ferenc; Boonstra, Piet W; van Boven, Ad J; Ungi, Imre; Bogáts, Gabor; Man-
sour, Samer; Noiseux, Nicolas; Sabaté, Manel; Pomar, Jose; Hickey, Mark; Gershlick, Anthony; Buszman,
Pawel E; Bochenek, Andrzej; Schampaert, Erick; Pagé, Pierre; Modolo, Rodrigo; Gregson, John; Simon-
ton, Charles A (2019). Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. New
England Journal of Medicine, 381(19):1820-1830.
DOI: https://doi.org/10.1056/NEJMoa1909406
2
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 381;19 nejm.org November 7, 20191820
The authors’ full names, academic de-
grees, and affiliations are listed in the 
Appendix. Address reprint requests to 
Dr. Stone at the Cardiovascular Research 
Foundation, 1700 Broadway, 8th Fl., New 
York, NY 10019, or at  gstone@ crf . org.
*A complete list of investigators, institu-
tions, and research organizations partici-
pating in the EXCEL trial is provided in 
the Supplementary Appendix, available at 
NEJM.org.
This article was published on September 
28, 2019, at NEJM.org.
N Engl J Med 2019;381:1820-30.
DOI: 10.1056/NEJMoa1909406
Copyright © 2019 Massachusetts Medical Society.
BACKGROUND
Long-term outcomes after percutaneous coronary intervention (PCI) with contem-
porary drug-eluting stents, as compared with coronary-artery bypass grafting 
(CABG), in patients with left main coronary artery disease are not clearly estab-
lished.
METHODS
We randomly assigned 1905 patients with left main coronary artery disease of low 
or intermediate anatomical complexity (according to assessment at the participating 
centers) to undergo either PCI with fluoropolymer-based cobalt–chromium everoli-
mus-eluting stents (PCI group, 948 patients) or CABG (CABG group, 957 patients). 
The primary outcome was a composite of death, stroke, or myocardial infarction.
RESULTS
At 5 years, a primary outcome event had occurred in 22.0% of the patients in the 
PCI group and in 19.2% of the patients in the CABG group (difference, 2.8 percent-
age points; 95% confidence interval [CI], −0.9 to 6.5; P = 0.13). Death from any cause 
occurred more frequently in the PCI group than in the CABG group (in 13.0% vs. 
9.9%; difference, 3.1 percentage points; 95% CI, 0.2 to 6.1). In the PCI and CABG 
groups, the incidences of definite cardiovascular death (5.0% and 4.5%, respec-
tively; difference, 0.5 percentage points; 95% CI, −1.4 to 2.5) and myocardial infarc-
tion (10.6% and 9.1%; difference, 1.4 percentage points; 95% CI, −1.3 to 4.2) were 
not significantly different. All cerebrovascular events were less frequent after PCI 
than after CABG (3.3% vs. 5.2%; difference, −1.9 percentage points; 95% CI, −3.8 
to 0), although the incidence of stroke was not significantly different between the 
two groups (2.9% and 3.7%; difference, −0.8 percentage points; 95% CI, −2.4 to 0.9). 
Ischemia-driven revascularization was more frequent after PCI than after CABG 
(16.9% vs. 10.0%; difference, 6.9 percentage points; 95% CI, 3.7 to 10.0).
CONCLUSIONS
In patients with left main coronary artery disease of low or intermediate anatomical 
complexity, there was no significant difference between PCI and CABG with respect 
to the rate of the composite outcome of death, stroke, or myocardial infarction at 
5 years. (Funded by Abbott Vascular; EXCEL ClinicalTrials.gov number, NCT01205776.)
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P
ercutaneous coronary intervention 
(PCI) with drug-eluting stents has emerged 
as an acceptable treatment for selected pa-
tients with left main coronary artery disease.1-8 
However, long-term data from randomized trials 
comparing PCI involving contemporary drug-
eluting stents with coronary-artery bypass graft-
ing (CABG) in these patients are lacking. In the 
Evaluation of XIENCE versus Coronary Artery 
Bypass Surgery for Effectiveness of Left Main 
Revascularization (EXCEL) trial,2 which involved 
patients with left main coronary artery disease 
of low or intermediate anatomical complexity, 
PCI with everolimus-eluting stents was noninferior 
to CABG with respect to the primary composite 
outcome measure of death, stroke, or myocardial 
infarction at a median 3-year follow-up. However, 
although the incidence of periprocedural adverse 
events (within 30 days) was lower in the PCI 
group, patients in the CABG group had fewer 
adverse events between 30 days and 3 years after 
the procedure. To further characterize the long-
term outcomes of PCI as compared with CABG 
in patients with left main coronary artery dis-




The trial design has been described previously.2,9 
In brief, we performed an international, open-
label, multicenter, randomized trial that com-
pared PCI involving thin-strut cobalt–chromium 
fluoropolymer-based everolimus-eluting stents 
(XIENCE, Abbott Vascular) with CABG in patients 
with left main coronary artery disease. The orga-
nization of the trial is described and participat-
ing centers are listed in the Supplementary Appen-
dix, available with the full text of this article at 
NEJM.org. The protocol, also available at NEJM 
.org, was designed by the principal investigators 
and trial committees, in which interventional 
cardiologists and cardiac surgeons were repre-
sented equally. The trial was approved by the 
investigational review board or ethics committee 
at each participating center, and written informed 
consent was obtained from all the patients. The 
trial was sponsored by Abbott Vascular, which 
participated in the design of the protocol and in 
the selection and management of the sites but 
was not involved in the management or analysis 
of the data or preparation of the manuscript, 
although it had the right to a nonbinding review 
of the manuscript. The principal investigators 
had unrestricted access to the data, prepared the 
manuscript, and vouch for the completeness and 
accuracy of the data and analyses and for the 
fidelity of the trial to the protocol.
Enrollment, Randomization, and Follow-up
Patients were eligible to participate in the trial if 
they had stenosis of the left main coronary ar-
tery of 70% or more (as estimated visually) or 
stenosis of 50% to less than 70% (if determined 
by means of noninvasive or invasive testing to be 
hemodynamically significant) and if a consensus 
among the members of the heart team had been 
reached regarding eligibility for revasculariza-
tion with either PCI or CABG (Table S1 in the 
Supplementary Appendix).2,9 In addition, eligible 
patients had low or intermediate anatomical com-
plexity of coronary artery disease, as assessed at 
the participating center and defined by a Synergy 
between Percutaneous Coronary Intervention with 
Taxus and Cardiac Surgery (SYNTAX) score of 32 
or less.10 The SYNTAX score reflects a compre-
hensive angiographic assessment of the coro-
nary vasculature, with 0 as the lowest score, and 
higher scores (no upper limit) indicating more 
complex coronary anatomy.
Randomization was performed with the use 
of an interactive voice-based or Web-based sys-
tem in block sizes of 16, 24, or 32, with stratifi-
cation according to the presence or absence of 
diabetes, SYNTAX score, and trial center. Clinical 
follow-up was performed at 1 month, 6 months, 
and 1 year and then annually through 5 years. 
Guideline-directed medical therapy and man-
agement of risk factors were recommended for 
all the patients, as previously described.9 Dual 
antiplatelet therapy was administered before PCI 
and for a minimum of 1 year thereafter. Aspirin 
was administered before and after CABG, and 
the use of clopidogrel during follow-up was al-
lowed but not mandatory. Routine angiographic 
follow-up was not permitted.
Outcomes
The primary outcome was the composite of death 
from any cause, stroke, or myocardial infarction 
at 3 years. Major secondary outcomes included 
the primary outcome measure at 30 days and the 
composite of death, stroke, myocardial infarction, 
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or ischemia-driven revascularization at 3 years. 
The cause of death was adjudicated as definite 
cardiovascular, definite noncardiovascular, or un-
determined, and undetermined cases were con-
servatively classified as cardiovascular. Long-term 
additional secondary outcomes included these 
measures and their components at 5 years, as 
well as therapy failure (definite stent thrombosis 
or symptomatic graft stenosis or occlusion), all 
revascularizations, and all cerebrovascular events 
(stroke or transient ischemic attack). Outcomes 
are defined in Table S2. Trial monitors collected 
source documents of all primary and secondary 
outcome events for adjudication by an indepen-
dent events committee. The extent of disease 
and SYNTAX score were assessed at an angio-
graphic core laboratory.
Statistical Analysis
The trial was powered to show the noninferior-
ity of PCI to CABG with respect to the primary 
outcome at 3 years.2,9 The 5-year secondary out-
comes were prespecified but were not explicitly 
powered or adjusted for multiple comparisons. 
The principal analyses were performed in the 
intention-to-treat population, which included all 
patients according to the group to which they 
were randomly assigned, regardless of the treat-
ment received. Sensitivity analyses were per-
formed in the per-protocol and as-treated popu-
lations,9 with multiple imputation to account for 
missing follow-up data.11
Event rates were based on Kaplan–Meier esti-
mates in time-to-first-event analyses. However, 
the underlying assumption of proportional haz-
ards in the Cox model for the primary and major 
secondary outcomes from randomization through 
5 years was not met (treatment–time interaction, 
P<0.001). Principal comparisons between treat-
ments were therefore performed by logistic re-
gression with follow-up time included as a log-
transformed offset variable (no other covariates 
were included), with the use of an estimated 
standard error for the difference. In a post hoc 
analysis, we also evaluated piecewise hazards 
models separately within 0 to 30 days (the peri-
procedural period), 30 days to 1 year (the major 
risk period for stent restenosis), and 1 year to 
5 years (long-term follow-up) — intervals during 
which proportional hazards were preserved. Given 
the presence of nonproportional hazards, net 
treatment effects were also examined with the 
use of post hoc milestone and restricted mean 
survival time analyses (Table S3). For milestone 
analysis, the percentage of patients with an event 
in each group was estimated with the Kaplan–
Meier method, and Greenwood’s formula was 
used to estimate standard errors. The difference 
between groups in milestone event rates that 
occurred each day during the 5-year follow-up 
period is reported. Restricted mean event-free 
survival time is the mean time free from an 
outcome event adjusted for loss to follow-up, 
reflecting the area under the survival curve.12 
The difference between groups in the restricted 
mean survival time over the 5-year follow-up 
period is reported.
Categorical variables were compared with the 
use of the chi-square test or Fisher’s exact test. 
Continuous variables were compared with the 
use of Student’s t-test or the Wilcoxon rank-sum 
test for non-normally distributed data. For supe-
riority, a two-sided P value of less than 0.05 was 
considered to indicate statistical significance. The 
95% confidence intervals for secondary outcomes 
were not adjusted for multiple comparisons, and 
therefore inferences drawn from these intervals 
may not be reproducible. All statistical analyses 
were performed with the use of SAS software, 
version 9.4 (SAS Institute).
R esult s
Patients and Procedures
From September 29, 2010, to March 6, 2014, a 
total of 1905 patients with left main coronary 
artery disease were randomly assigned at 126 
sites in 17 countries to PCI (948 patients) or 
CABG (957 patients) (Fig. S1). Baseline clinical 
and angiographic characteristics were well bal-
anced between the groups (Tables S4 and S5). 
The mean (±SD) age of the patients was 66.0±9.6 
years, 76.9% of patients were male, and 29.1% 
had diabetes. The mean SYNTAX score was 
20.6±6.2 according to assessment at local sites 
and 26.5±9.3 according to the angiographic core 
laboratory analysis, and 80.5% of the patients 
had distal left main bifurcation disease. Proce-
dural data are shown in Table S6. Adherence to 
guideline-directed medical therapy was high, 
although medication use differed between the 
groups during follow-up (Table S7).
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Primary Outcome
Five-year follow-up was achieved in 93.2% and 
90.1% of the PCI and CABG groups, respectively. 
The primary composite of death, stroke, or myo-
cardial infarction at 5 years occurred in 22.0% 
of the patients in the PCI group and 19.2% of 
the patients in the CABG group (difference, 2.8 
percentage points; 95% confidence interval [CI], 
−0.9 to 6.5; P = 0.13) (Table 1 and Fig. 1A). The 
hazard ratios (PCI vs. CABG) for the primary out-
Outcome
PCI 
 (N = 948)
CABG 
 (N = 957)
Difference in 




Events Event Rate Events Event Rate
no. % no. % percentage points
Primary outcome
Death, stroke, or myocardial infarction 203 22.0 176 19.2 2.8 (−0.9 to 6.5) 1.19 (0.95 to 1.50)
Secondary outcomes
Death, stroke, myocardial infarction, or 
ischemia-driven revascularization
290 31.3 228 24.9 6.5 (2.4 to 10.6) 1.39 (1.13 to 1.71)
Death from any cause 119 13.0 89 9.9 3.1 (0.2 to 6.1) 1.38 (1.03 to 1.85)
Cardiovascular 61 6.8 49 5.5 1.3 (−0.9 to 3.6) 1.26 (0.85 to 1.85)
Definite cardiovascular 45 5.0 40 4.5 0.5 (−1.4 to 2.5) 1.13 (0.73 to 1.74)
Undetermined cause 16 1.9 9 1.1 0.9 (−0.3 to 2.0) 1.78 (0.78 to 4.06)
Noncardiovascular 58 6.6 40 4.6 2.0 (−0.2 to 4.2) 1.47 (0.97 to 2.23)
Stroke 26 2.9 33 3.7 −0.8 (−2.4 to 0.9) 0.78 (0.46 to 1.31)
Myocardial infarction 95 10.6 84 9.1 1.4 (−1.3 to 4.2) 1.14 (0.84 to 1.55)
Periprocedural 37 3.9 57 6.1 −2.1 (−4.1 to −0.1) 0.63 (0.41 to 0.96)
Nonperiprocedural 59 6.8 31 3.5 3.2 (1.2 to 5.3) 1.96 (1.25 to 3.06)
Ischemia-driven revascularization 150 16.9 88 10.0 6.9 (3.7 to 10.0) 1.84 (1.39 to 2.44)
PCI 125 14.1 80 9.1 4.9 (1.9 to 7.9) 1.65 (1.22 to 2.22)
CABG 38 4.3 8 0.9 3.4 (1.9 to 4.9) 4.90 (2.27 to 10.56)
Additional outcomes
Any revascularization 153 17.2 92 10.5 6.7 (3.5 to 9.9) 1.79 (1.36 to 2.36)
Stent thrombosis 16 1.8 0 0 — —
Definite 10 1.1 0 0 — —
Probable 6 0.7 0 0 — —
Symptomatic graft stenosis or occlusion 0 0 58 6.5 — —
Therapy failure† 10 1.1 58 6.5 −5.4 (−7.2 to −3.6) 0.16 (0.08 to 0.32)
Cerebrovascular events‡ 29 3.3 46 5.2 −1.9 (−3.8 to 0) 0.61 (0.38 to 0.99)
Transient ischemic attack 3 0.3 14 1.6 −1.3 (−2.2 to −0.4) 0.21 (0.06 to 0.74)
*  Event rates were based on Kaplan–Meier estimates in time-to-first-event analyses; thus, the rate is not the same as the ratio of the numera-
tor and denominator. Odds ratios and 95% confidence intervals were estimated from logistic regression with follow-up time included as a 
log-transformed offset variable. The 95% confidence intervals for secondary outcomes have not been adjusted for multiple comparisons, 
and therefore inferences drawn from these intervals may not be reproducible. CABG denotes coronary-artery bypass grafting, and PCI per-
cutaneous coronary intervention.
†  Therapy failure was defined as definite stent thrombosis or symptomatic graft stenosis or occlusion.
‡  Cerebrovascular events were stroke or transient ischemic attack.
Table 1. Primary and Secondary Clinical Outcomes at 5 Years.*
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come varied in the three periods between 0 to 30 
days (hazard ratio, 0.61; 95% CI, 0.42 to 0.88), 
30 days to 1 year (hazard ratio, 1.07; 95% CI, 
0.68 to 1.70), and 1 year to 5 years (hazard ratio, 
1.61; 95% CI, 1.23 to 2.12) (Table 2 and Fig. S2). 
Analyses of milestones and restricted mean sur-
vival time showed that the early benefit of PCI 
was gradually diminished over time by increased 
postprocedural risk (Fig. S3). Mean event-free 
survival through 5 years was 5.2 days (95% CI, 
−46.1 to 56.5) longer after PCI than after CABG. 
The treatment effect for the primary outcome in 
prespecified subgroups is shown in Figure 2. 
Results were similar in the per-protocol and as-
treated populations and after multiple imputa-
tion accounting for missing follow-up data (Ta-
bles S8 and S9).
Secondary Outcomes
The secondary composite outcome of death, 
stroke, myocardial infarction, or ischemia-driven 
revascularization at 5 years occurred in 31.3% of 
the patients in the PCI group and 24.9% of the 
patients in the CABG group (difference, 6.5 per-
centage points; 95% CI, 2.4 to 10.6) (Table 1 and 
Fig. 1B). The incidences of the individual compo-
nents of the primary and secondary composite 
outcomes are shown in Table 1 and Figure 3. 
Death from any cause occurred in 13.0% of the 
patients in the PCI group and 9.9% of the pa-
tients in the CABG group (difference, 3.1 per-
centage points; 95% CI, 0.2 to 6.1). Eighteen of 
the 30 excess deaths in the PCI group were ad-
judicated as noncardiovascular deaths, 5 as defi-
nite cardiovascular deaths, and 7 as being of 
undetermined cause (Table S10). The results were 
similar after accounting for patients who were 
lost to follow-up (Table S9). The incidences of 
stroke and myocardial infarction at 5 years did 
not differ significantly between the PCI group 
and the CABG group. Ischemia-driven revascu-
larization within 5 years was performed more 
frequently after PCI than after CABG, whereas 
the incidences of all cerebrovascular events and 
definite stent thrombosis or symptomatic graft 
stenosis or occlusion at 5 years were less fre-
quent with PCI than with CABG. The hazard 
ratios for the secondary outcomes between 0 to 
30 days, 30 days to 1 year, and 1 year to 5 years 
are provided in Table 2.
Figure 1. Time-to-First-Event Curves for the Primary and Secondary Composite 
Outcomes through 5-Year Follow-up.
Panel A shows the results of the primary composite outcome of death from 
any cause, stroke, or myocardial infarction. Panel B shows the results of 
the secondary composite outcome of death from any cause, stroke, myo-
cardial infarction, or ischemia-driven revascularization. Event rates were 
based on Kaplan–Meier estimates. Given nonproportional hazards during 
the follow-up period, logistic regression with follow-up time included as a 
log-transformed offset variable was used to calculate the odds ratios with 
95% confidence intervals. The 95% confidence intervals for secondary out-
comes have not been adjusted for multiple comparisons, and therefore in-
ferences drawn from these intervals may not be reproducible. In each panel, 
the inset shows the same data on an enlarged y axis. CABG denotes coro-
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Discussion
Patients with left main coronary artery disease 
have a poor prognosis because of the large 
amount of myocardium at risk.13 Survival among 
patients with left main coronary artery disease 
is longer after revascularization with either PCI 
or CABG than with medical therapy alone.14 In 
six randomized trials involving patients with left 




Events Event Rate Events Event Rate
no./no. of patients % no./no. of patients %
Outcomes at 30 days
Death, stroke, or myocardial infarction 46/948 4.9 75/957 8.0 0.61 (0.42–0.88)
Death 9/948 1.0 10/957 1.1 0.90 (0.37–2.21)
Stroke 6/948 0.6 12/957 1.3 0.50 (0.19–1.32)
Myocardial infarction 37/948 3.9 59/957 6.3 0.63 (0.42–0.94)
Death, stroke, myocardial infarction, or 
 ischemia-driven revascularization
46/948 4.9 80/957 8.5 0.57 (0.40–0.82)
Ischemia-driven revascularization 6/948 0.6 13/957 1.4 0.46 (0.17–1.21)
Definite stent thrombosis or symptomatic 
graft stenosis or occlusion
3/948 0.3 11/957 1.2 0.27 (0.08–0.97)
Outcomes from 30 days to 1 yr
Death, stroke, or myocardial infarction 38/948 4.1 35/957 3.8 1.07 (0.68–1.70)
Death 22/948 2.4 23/957 2.5 0.94 (0.53–1.69)
Stroke 5/948 0.5 7/957 0.8 0.71 (0.22–2.23)
Myocardial infarction 16/948 1.7 10/957 1.1 1.58 (0.72–3.48)
Death, stroke, myocardial infarction, or 
 ischemia-driven revascularization
83/948 8.9 56/957 6.1 1.48 (1.05–2.07)
Ischemia-driven revascularization 59/948 6.4 28/957 3.1 2.10 (1.34– 3.30)
Definite stent thrombosis or symptomatic 
graft stenosis or occlusion
0/948 0 22/957 2.4 —
Outcomes from 1 yr to 5 yr
Death, stroke, or myocardial infarction 133/933 15.1 83/929 9.7 1.61 (1.23–2.12)
Death 88/933 10.0 56/929 6.6 1.57 (1.12–2.19)
Stroke 16/933 1.9 15/929 1.8 1.06 (0.52–2.15)
Myocardial infarction 43/933 5.1 20/929 2.4 2.16 (1.27–3.67)
Death, stroke, myocardial infarction, or 
 ischemia-driven revascularization
198/933 22.4 118/929 13.8 1.74 (1.38–2.18)
Ischemia-driven revascularization 100/933 11.6 49/929 5.8 2.10 (1.49–2.95)
Definite stent thrombosis or symptomatic 
graft stenosis or occlusion
7/933 0.8 25/929 3.0 0.28 (0.12–0.64)
*  Event rates were based on Kaplan–Meier estimates in time-to-first-event analyses; thus, the rate is not the same as the ratio of the numera-
tor and denominator. The landmark period from 30 days to 5 years includes all randomly assigned patients at day 30 except those who died 
before day 30. Thus, some patients with a stroke, myocardial infarction, or ischemia-driven revascularization within 30 days may have had a 
second event between 30 days and 5 years. The 95% confidence intervals for secondary outcomes have not been adjusted for multiple com-
parisons, and therefore inferences drawn from these intervals may not be reproducible.
Table 2. Primary and Secondary Outcomes over Three Periods.*
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Figure 2. Subgroup Analyses of the Primary Composite Outcome at 5 Years.
Event rates were based on Kaplan–Meier estimates; thus, the rate is not the same as the ratio of the numerator and denominator. There were no significant differences between 
the relative risks of the treatment effects in any of the subgroups. The estimated glomerular filtration rate (GFR) was calculated by means of the Cockcroft–Gault equation. The 
Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) score reflects a comprehensive angiographic assessment of the coronary vascula-
ture, with 0 as the lowest score, and higher scores (no upper limit) indicating more complex coronary anatomy. The 95% confidence intervals for secondary outcomes have not 
been adjusted for multiple comparisons, and therefore inferences drawn from these intervals may not be reproducible.
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eluting stents was associated with more favor-
able outcomes at 1 year than CABG, with fewer 
periprocedural adverse events and more rapid 
recovery.3,4,15 Conversely, conflicting long-term 
findings from these trials have been reported.1,3-5 
However, to achieve adequate power, these trials 
relied on differences in the incidence of repeat 
revascularization, an outcome of lesser impor-
tance to physicians and patients than death, 
stroke, and myocardial infarction.16 The degree 
of deterioration in health status that triggers 
repeat revascularization is also greater after 
CABG than after PCI; this calls into question the 
parity of this outcome.17,18 In addition, previous 
trials did not use contemporary drug-eluting 
stents, which have a better safety profile than 
that of earlier devices.
The present trial was powered to examine the 
composite rate of death, stroke, or myocardial 
infarction. Current-generation f luoropolymer-
Figure 3. Time-to-First-Event Curves for the Components of the Primary and Secondary Composite Outcomes through 5-Year Follow-up.
Results of analyses of the components of the primary and secondary composite outcomes are shown in Panel A (death from any cause), 
Panel B (stroke), Panel C (myocardial infarction), and Panel D (ischemia-driven revascularization). Event rates were based on Kaplan–
Meier estimates. Given nonproportional hazards during the follow-up period, logistic regression with follow-up time included as a log-
transformed offset variable was used to calculate the odds ratios with 95% confidence intervals. The 95% confidence intervals for sec-
ondary outcomes have not been adjusted for multiple comparisons, and therefore inferences drawn from these intervals may not be 
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based thin-strut cobalt–chromium everolimus-
eluting stents, which are associated with a low 
incidence of stent thrombosis, were used,19,20 and 
contemporary CABG techniques were incorpo-
rated.2,9 We did not detect a significant differ-
ence in the composite rate of death, stroke, or 
myocardial infarction at 5 years between patients 
with left main coronary artery disease and low 
or intermediate anatomical complexity (as de-
fined by a site-reported SYNTAX score of ≤32) 
who underwent PCI and those who underwent 
CABG. This finding was consistent across impor-
tant subgroups, including patients with diabetes 
and those without diabetes and patients with 
lower and higher SYNTAX scores. However, in-
terpreting these results as showing no difference 
between treatments is simplistic. As shown by 
the piecewise hazards analysis, three distinct 
periods of relative risk were present: from 0 to 
30 days, when PCI resulted in fewer primary 
outcome events than CABG; from 30 days to 1 year, 
when the incidence of the events was similar 
among patients in each treatment group; and 
from 1 to 5 years, when primary outcome events 
were less common after CABG than after PCI. 
Consideration of the differential timing of risk 
is clinically relevant, since earlier exposure to 
adverse events has a more profound influence on 
the long-term burden of disease than exposure 
to events occurring later. As shown by the analy-
sis of milestones and restricted mean survival 
time, by 5 years, the early benefit of PCI due to 
reduced periprocedural risk was attenuated by 
the greater number of events that occurred dur-
ing follow-up than with CABG, such that the 
cumulative mean time free from adverse events 
was similar in the two treatment groups.
There were numerical differences between 
PCI and CABG in several nonpowered secondary 
outcomes. The event rates of death from any 
cause (a 3.1-percentage-point difference between 
the groups) and repeat revascularization (a 6.9- 
percentage-point difference) favored CABG, 
whereas event rates of cerebrovascular events (a 
1.9-percentage-point difference) and therapy fail-
ure (a 5.4-percentage-point difference) favored 
PCI. Rates of myocardial infarction at 5 years 
were similar in the two groups, but they favored 
PCI in the periprocedural period and CABG dur-
ing long-term follow-up. Although some of these 
findings may indicate true treatment effects, 
they must be interpreted cautiously, since more 
than 20 secondary outcomes were assessed and 
analyses were not adjusted for multiple com-
parisons. Nonetheless, several findings warrant 
comment.
Although the cause of death can sometimes 
be ambiguous, rates of adjudicated definite car-
diovascular death were similar among patients 
who underwent PCI and those who underwent 
CABG, consistent with the similar rates of myo-
cardial infarction at 5 years. The difference in all-
cause mortality between the groups was driven 
by noncardiovascular deaths, especially those 
from cancer and infection, which occurred more 
commonly after PCI during late follow-up. The 
finding of a possible excess of deaths from any 
cause after PCI is at odds with the similar rates 
of death at 5 years among patients who under-
went PCI and among those who underwent 
CABG in the contemporary Nordic–Baltic–British 
Left Main Revascularization (NOBLE) trial,3 an 
individual patient-data pooled analysis of six 
randomized trials involving 4478 patients with 
left main coronary artery disease, and in other 
meta-analyses4,21 and with the similar mortality 
at 10 years after PCI and CABG among patients 
with left main coronary artery disease in the 
SYNTAX trial.22
Whereas previous studies have shown higher 
rates of stroke after CABG than after PCI,23 the 
excess of cerebrovascular events after CABG in 
the present trial was driven more by transient 
ischemic attacks than by strokes. The greater 
observed incidence of repeat revascularization 
after the use of drug-eluting stents than after 
CABG is consistent with previous analyses, but 
most revascularization events were repeat PCI 
procedures; only 1 of 25 patients initially treated 
with everolimus-eluting stents underwent CABG 
within 5 years. Nonetheless, repeat revasculariza-
tion procedures may be associated with myocar-
dial infarction and death.24 These considerations 
notwithstanding, the absolute 5-year differences 
between the groups with respect to all the second-
ary outcomes were relatively modest, and some 
may have been due to chance. This perspective 
should be considered in discussions between 
the heart team and the patient when weighing 
the pros and cons of the different therapies.25
Additional limitations of this trial should be 
considered. First, bias in event ascertainment 
cannot be ruled out given the open-label trial 
design. Second, although the trial excluded pa-
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tients with high SYNTAX scores, approximately 
25% of the patients met this criterion according 
to the core laboratory analysis. Although the pri-
mary outcome results were consistent in this 
subgroup, further studies are needed to deter-
mine the most appropriate treatment for patients 
with left main coronary artery disease and high 
anatomical complexity. Third, a specific bio-
marker-based definition of large periprocedural 
myocardial infarction was used in the present 
trial2,6; this definition differs from the criteria 
used in the Third Universal Definition of Myo-
cardial Infarction26 (which was developed while 
the current trial was ongoing) and the Fourth 
Universal Definition of Myocardial Infarction27 
(which was developed subsequently). The defini-
tion used in the EXCEL trial is based on previ-
ously established criteria that have been shown 
to be prognostically relevant after PCI and after 
CABG and that minimize ascertainment bias.28 
As previously reported, the occurrence of peri-
procedural myocardial infarction according to 
this protocol definition was independently pre-
dictive of late death from cardiovascular causes 
and death from any cause after PCI and after 
CABG, whereas lesser degrees of elevated levels 
of biomarkers were not.29 Fourth, patients who 
underwent PCI, as compared with those who 
underwent CABG, more commonly received dual 
antiplatelet therapy and inhibitors of the renin–
angiotensin axis during follow-up, whereas pa-
tients who underwent CABG more commonly 
received oral anticoagulants, beta-blockers, diu-
retics, and antiarrhythmic agents; these differ-
ences reflect inherent differences between the 
procedures and their resulting complications. 
The extent to which variability in medication use 
contributed to the present results is uncertain. 
Finally, follow-up was limited to 5 years, and at 
this time point the hazard curves were continu-
ing to diverge. Ten-year (or longer) follow-up is 
needed to characterize the very late safety pro-
files of PCI and CABG, since both stents and 
bypass grafts progressively fail over time.
In conclusion, in the present trial we did not 
find a significant difference between PCI and 
CABG with respect to rates of the composite 
outcome of death, stroke, or myocardial infarction 
at 5 years among patients with left main coro-
nary artery disease and low or intermediate ana-
tomical complexity (as defined by the SYNTAX 
score) according to assessment at the participat-
ing centers.
A data sharing statement provided by the authors is available 
with the full text of this article at NEJM.org.
Supported by Abbott Vascular.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
Appendix
The authors’ full names and academic degrees are as follows: Gregg W. Stone, M.D., A. Pieter Kappetein, M.D., Ph.D., Joseph F. Sabik, 
M.D., Stuart J. Pocock, Ph.D., Marie-Claude Morice, M.D., John Puskas, M.D., David E. Kandzari, M.D., Dimitri Karmpaliotis, M.D., 
W. Morris Brown III, M.D., Nicholas J. Lembo, M.D., Adrian Banning, M.D., Béla Merkely, M.D., Ferenc Horkay, M.D., Piet W. Boonstra, 
M.D., Ad J. van Boven, M.D., Imre Ungi, M.D., Gabor Bogáts, M.D., Samer Mansour, M.D., Nicolas Noiseux, M.D., Manel Sabaté, M.D., 
Jose Pomar, M.D., Mark Hickey, M.D., Anthony Gershlick, M.D., Pawel E. Buszman, M.D., Andrzej Bochenek, M.D., Erick Schampaert, 
M.D., Pierre Pagé, M.D., Rodrigo Modolo, M.D., Ph.D., John Gregson, Ph.D., Charles A. Simonton, M.D., Roxana Mehran, M.D., 
Ioanna Kosmidou, M.D., Philippe Généreux, M.D., Aaron Crowley, M.A., Ovidiu Dressler, M.D., and Patrick W. Serruys, M.D., Ph.D.
The authors’ affiliations are as follows: the Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount 
Sinai (G.W.S., R. Mehran), the Cardiovascular Research Foundation (G.W.S., D.K., N.J.L., R. Mehran, I.K., P.G., A.C., O.D.), Mount Sinai 
Heart at Mount Sinai Saint Luke’s (J. Puskas), and New York–Presbyterian Hospital and Columbia University Medical Center (D.K., 
N.J.L., I.K.) — all in New York; Erasmus Medical Center, Rotterdam (A.P.K.), Medisch Centrum Leeuwarden, Leeuwarden (P.W.B., 
A.J.B.), and Academic Medical Center, University of Amsterdam, Amsterdam (R. Modolo) — all in the Netherlands; University Hospitals 
Cleveland Medical Center, Cleveland (J.F.S.); the London School of Hygiene and Tropical Medicine (S.J.P., J.G.) and the International 
Centre for Circulatory Health, National Heart and Lung Institute, Imperial College London (P.W.S.), London, John Radcliffe Hospital, 
Oxford (A. Banning), and University Hospitals of Leicester NHS Trust, Leicester (M.H., A.G.) — all in the United Kingdom; Hôpital Privé 
Jacques Cartier, Ramsay Générale de Santé, Massy, France (M.-C.M.); Piedmont Heart Institute, Atlanta (D.E.K., W.M.B.); Semmelweis 
University, Budapest (B.M., F.H.), and the University of Szeged, Szeged (I.U., G.B.) — both in Hungary; Centre Hospitalier de l’Université 
de Montréal (S.M., N.N.) and Hôpital du Sacré-Coeur de Montréal (E.S., P.P., P.G.), Montreal; Hospital Clinic, Barcelona (M.S., 
J. Pomar); Medical University of Silesia, Katowice, and American Heart of Poland, Ustron — both in Poland (P.E.B., A. Bochenek); Univer-
sity of Campinas, Campinas, Brazil (R. Modolo); Abbott Vascular, Santa Clara, CA (C.A.S.); and Gagnon Cardiovascular Institute, Morris-
town Medical Center, Morristown, NJ (P.G.).
References
1. Morice MC, Serruys PW, Kappetein AP, 
et al. Five-year outcomes in patients with 
left main disease treated with either per-
cutaneous coronary intervention or coro-
nary artery bypass grafting in the Synergy 
between Percutaneous Coronary Interven-
tion with Taxus and Cardiac Surgery Trial. 
Circulation 2014; 129: 2388-94.
2. Stone GW, Sabik JF, Serruys PW, et al. 
The New England Journal of Medicine 
Downloaded from nejm.org by TIZIANO MOCCETTI on January 2, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
n engl j med 381;19 nejm.org November 7, 20191830
PCI or CABG for Left Main Coronary Disease
Everolimus-eluting stents or bypass sur-
gery for left main coronary artery disease. 
N Engl J Med 2016; 375: 2223-35.
3. Mäkikallio T, Holm NR, Lindsay M, 
et al. Percutaneous coronary angioplasty 
versus coronary artery bypass grafting in 
treatment of unprotected left main steno-
sis (NOBLE): a prospective, randomised, 
open-label, non-inferiority trial. Lancet 
2016; 388: 2743-52.
4. Palmerini T, Serruys P, Kappetein AP, 
et al. Clinical outcomes with percutane-
ous coronary revascularization vs coro-
nary artery bypass grafting surgery in 
patients with unprotected left main coro-
nary artery disease: a meta-analysis of 
6 randomized trials and 4,686 patients. 
Am Heart J 2017; 190: 54-63.
5. Laukkanen JA, Kunutsor SK, Niemelä 
M, Kervinen K, Thuesen L, Mäkikallio TH. 
All-cause mortality and major cardiovas-
cular outcomes comparing percutaneous 
coronary angioplasty versus coronary ar-
tery bypass grafting in the treatment of 
unprotected left main stenosis: a meta-
analysis of short-term and long-term ran-
domised trials. Open Heart 2017; 4(2): 
e000638.
6. Fihn SD, Blankenship JC, Alexander KP, 
et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS 
focused update of the guideline for the 
diagnosis and management of patients 
with stable ischemic heart disease: a report 
of the American College of Cardiology/
American Heart Association Task Force 
on Practice Guidelines, and the American 
Association for Thoracic Surgery, Preven-
tive Cardiovascular Nurses Association, 
Society for Cardiovascular Angiography 
and Interventions, and Society of Thoracic 
Surgeons. J Am Coll Cardiol 2014; 64: 
1929-49.
7. Patel MR, Calhoon JH, Dehmer GJ, et al. 
ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 
2017 appropriate use criteria for coronary 
revascularization in patients with stable 
ischemic heart disease: a report of the 
American College of Cardiology Appro-
priate Use Criteria Task Force, American 
Association for Thoracic Surgery, Ameri-
can Heart Association, American Society 
of Echocardiography, American Society of 
Nuclear Cardiology, Society for Cardio-
vascular Angiography and Interventions, 
Society of Cardiovascular Computed To-
mography, and Society of Thoracic Sur-
geons. J Am Coll Cardiol 2017; 69: 2212-41.
8. Windecker S, Neumann FJ, Jüni P, 
Sousa-Uva M, Falk V. Considerations for 
the choice between coronary artery bypass 
grafting and percutaneous coronary in-
tervention as revascularization strategies 
in major categories of patients with stable 
multivessel coronary artery disease: an 
accompanying article of the task force of 
the 2018 ESC/EACTS guidelines on myo-
cardial revascularization. Eur Heart J 2019; 
40: 204-12.
9. Kappetein AP, Serruys PW, Sabik JF, 
et al. Design and rationale for a random-
ised comparison of everolimus-eluting 
stents and coronary artery bypass graft 
surgery in selected patients with left main 
coronary artery disease: the EXCEL trial. 
EuroIntervention 2016; 12: 861-72.
10. SYNTAX score calculator (http://ir - nwr 
.ru/ calculators/ syntaxscore .htm).
11. Little RJ, D’Agostino R, Cohen ML, et al. 
The prevention and treatment of missing 
data in clinical trials. N Engl J Med 2012; 
367: 1355-60.
12. Royston P, Parmar MK. Restricted 
mean survival time: an alternative to the 
hazard ratio for the design and analysis of 
randomized trials with a time-to-event 
outcome. BMC Med Res Methodol 2013; 
13: 152.
13. Collet C, Capodanno D, Onuma Y, et al. 
Left main coronary artery disease: patho-
physiology, diagnosis, and treatment. Nat 
Rev Cardiol 2018; 15: 321-31.
14. Bittl JA, He Y, Jacobs AK, Yancy CW, 
Normand SL. Bayesian methods affirm 
the use of percutaneous coronary inter-
vention to improve survival in patients 
with unprotected left main coronary ar-
tery disease. Circulation 2013; 127: 2177-85.
15. Baron SJ, Chinnakondepalli K, Mag-
nuson EA, et al. Quality-of-life after evero-
limus-eluting stents or bypass surgery for 
left-main disease: results from the EXCEL 
Trial. J Am Coll Cardiol 2017; 70: 3113-22.
16. Stolker JM, Spertus JA, Cohen DJ, et al. 
Rethinking composite end points in clini-
cal trials: insights from patients and trial-
ists. Circulation 2014; 130: 1254-61.
17. Arnold SV, Magnuson EA, Wang K, et al. 
Do differences in repeat revascularization 
explain the antianginal benefits of bypass 
surgery versus percutaneous coronary in-
tervention? Implications for future treat-
ment comparisons. Circ Cardiovasc Qual 
Outcomes 2012; 5: 267-75.
18. Kazi DS, Hlatky MA. Repeat revascu-
larization is a faulty end point for clinical 
trials. Circ Cardiovasc Qual Outcomes 
2012; 5: 249-50.
19. Palmerini T, Biondi-Zoccai G, Della 
Riva D, et al. Clinical outcomes with bio-
absorbable polymer- versus durable poly-
mer-based drug-eluting and bare-metal 
stents: evidence from a comprehensive 
network meta-analysis. J Am Coll Cardiol 
2014; 63: 299-307.
20. Bangalore S, Kumar S, Fusaro M, et al. 
Short- and long-term outcomes with drug-
eluting and bare-metal coronary stents: 
a mixed-treatment comparison analysis 
of 117 762 patient-years of follow-up from 
randomized trials. Circulation 2012; 125: 
2873-91.
21. Head SJ, Milojevic M, Daemen J, et al. 
Mortality after coronary artery bypass 
grafting versus percutaneous coronary in-
tervention with stenting for coronary artery 
disease: a pooled analysis of individual 
patient data. Lancet 2018; 391: 939-48.
22. Thuijs DJFM, Kappetein AP, Serruys 
PW, et al. Percutaneous coronary interven-
tion versus coronary artery bypass graft-
ing in patients with three-vessel or left 
main coronary artery disease: 10-year 
follow-up of the multicentre randomised 
controlled SYNTAX trial. Lancet 2019 
September 2 (Epub ahead of print).
23. Head SJ, Milojevic M, Daemen J, et al. 
Stroke rates following surgical versus per-
cutaneous coronary revascularization. J Am 
Coll Cardiol 2018; 72: 386-98.
24. Palmerini T, Della Riva D, Biondi-
Zoccai G, et al. Mortality following non-
emergent, uncomplicated target lesion re-
vascularization after percutaneous coronary 
intervention: an individual patient data 
pooled analysis of 21 randomized trials 
and 32,524 patients. JACC Cardiovasc In-
terv 2018; 11: 892-902.
25. Walsh MN, Bove AA, Cross RR, et al. 
ACCF 2012 health policy statement on 
patient-centered care in cardiovascular 
medicine: a report of the American Col-
lege of Cardiology Foundation Clinical 
Quality Committee. J Am Coll Cardiol 
2012; 59: 2125-43.
26. Thygesen K, Alpert JS, Jaffe AS, et al. 
Third universal definition of myocardial 
infarction. Circulation 2012; 126: 2020-35.
27. Thygesen K, Alpert JS, Jaffe AS, et al. 
Fourth universal definition of myocardial 
infarction (2018). Circulation 2018; 138(20): 
e618-e651.
28. Moussa ID, Klein LW, Shah B, et al. 
Consideration of a new definition of clin-
ically relevant myocardial infarction after 
coronary revascularization: an expert con-
sensus document from the Society for Car-
diovascular Angiography and Interventions 
(SCAI). J Am Coll Cardiol 2013; 62: 1563-70.
29. Ben-Yehuda O, Chen S, Redfors B, 
et al. Impact of large periprocedural myo-
cardial infarction on mortality after per-
cutaneous coronary intervention and cor-
onary artery bypass grafting for left main 
disease: an analysis from the EXCEL trial. 
Eur Heart J 2019; 40: 1930-41.
Copyright © 2019 Massachusetts Medical Society.
The New England Journal of Medicine 
Downloaded from nejm.org by TIZIANO MOCCETTI on January 2, 2020. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
